

Date: 11 April 2025

Swissmedic, Swiss Agency for Therapeutic Products

## ***Swiss Public Assessment Report Extension of therapeutic indication***

### **RYBREVANT**

<b>International non-proprietary name:</b>	amivantamab
<b>Pharmaceutical form:</b>	concentrate for solution for infusion
<b>Dosage strength(s):</b>	350 mg/7 mL
<b>Route(s) of administration:</b>	intravenous use
<b>Marketing authorisation holder:</b>	Janssen-Cilag AG
<b>Marketing authorisation no.:</b>	68380
<b>Decision and decision date:</b>	approved on 23 December 2024

#### **Note:**

This assessment report is as adopted by Swissmedic with all information of a commercially confidential nature deleted.

SwissPARs are final documents that provide information on submissions at a particular point in time. They are not updated after publication.

**Table of contents**

**1 Terms, Definitions, Abbreviations.....3**

**2 Background information on the procedure .....4**

2.1 Applicant’s request(s) .....4

2.2 Indication and dosage.....4

2.2.1 Requested indication .....4

2.2.2 Approved indication .....4

2.2.3 Requested dosage .....4

2.2.4 Approved dosage .....4

2.3 Regulatory history (milestones) .....4

**3 Medical context.....5**

**4 Nonclinical aspects .....5**

**5 Clinical aspects .....6**

5.1 Efficacy.....6

5.2 Safety .....6

5.3 Final clinical benefit risk assessment.....7

**6 Risk management plan summary.....8**

**7 Appendix.....9**

## 1 Terms, Definitions, Abbreviations

ACP	Amivantamab, carboplatin and pemetrexed
AUC	Area under the plasma concentration-time curve
CHT	Chemotherapy
CI	Confidence interval
CP	Carboplatin and pemetrexed
DCO	Data cut-off
EGFR	Epidermal growth factor receptor
EMA	European Medicines Agency
EORTC-QLQ-C30	European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
ESMO	European Society for Medical Oncology
FDA	Food and Drug Administration (USA)
HR	Hazard ratio
ITT	Intention-to-treat
KM	Kaplan-Meier
LoQ	List of Questions
MAH	Marketing Authorisation Holder
MET	hepatocyte growth factor receptor (mesenchymal epithelial transition factor)
NCCN	National Comprehensive Cancer Network
NSCLC	Non-small cell lung cancer
ORR	Objective response rate
OS	Overall survival
PFS	Progression-free survival
QoL	Quality of life
RMP	Risk management plan
SwissPAR	Swiss Public Assessment Report
TEAE	Treatment-emergent adverse event
TKI	Tyrosine kinase inhibitor
TPA	Federal Act of 15 December 2000 on Medicinal Products and Medical Devices (SR 812.21)
TPO	Ordinance of 21 September 2018 on Therapeutic Products (SR 812.212.21)

## 2 Background information on the procedure

### 2.1 Applicant's request(s)

#### Extension(s) of the therapeutic indication(s)

The applicant requested the addition of a new therapeutic indication or modification of an approved one in accordance with Article 23 TPO.

### 2.2 Indication and dosage

#### 2.2.1 Requested indication

RYBREVANT in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating exon 20 insertion mutations in the epidermal growth factor receptor (EGFR).

#### 2.2.2 Approved indication

RYBREVANT in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations (see "Clinical Efficacy").

#### 2.2.3 Requested dosage

The proposed dose of amivantamab is 1,400 mg (for participants <80 kg body weight) or 1,750 mg (for participants ≥80 kg body weight), administered as an intravenous infusion once weekly through 4 weeks, then every 3 weeks with a dose of 1,750 mg (for participants <80 kg body weight) or 2,100 mg (for participants ≥80 kg body weight) starting at Week 7.

Carboplatin is administered intravenously at an AUC of 5 mg/mL per minute once every 3 weeks for up to 4 cycles, and pemetrexed is administered intravenously at 500 mg/m<sup>2</sup> body surface area once every 3 weeks.

#### 2.2.4 Approved dosage

(see appendix)

### 2.3 Regulatory history (milestones)

Application	1 December 2023
Formal control completed	7 December 2023
List of Questions (LoQ)	5 March 2024
Response to LoQ	5 May 2024
Preliminary decision	21 June 2024
Response to preliminary decision	9 September 2024
Second Preliminary decision	25 October 2024
Response to second preliminary decision	15 November 2024
Final decision	23 December 2024
Decision	approval

### 3 Medical context

EGFR mutations are the most prevalent driver mutations in NSCLC, being identified in ca. 10-15% of adenocarcinomas in Western populations. The most frequently identified EGFR mutations are Exon 19del and L858R, prevalent in 80-85% of patients with activating EGFR mutations. They can be effectively targeted by multiple EGFR tyrosine kinase inhibitors (TKIs). EGFR Exon 20 insertion mutations account for just 9% of all EGFR mutations<sup>1</sup> and are characterised by de novo resistance to most of the currently approved EGFR TKIs. At the current time, two drugs targeting exon 20 are approved in Switzerland for the 2<sup>nd</sup> line treatment of NSCLC with EGFR Exon 20 insertion tumour mutations: amivantamab and mobocertinib. The preferred 1<sup>st</sup> line treatment for NSCLC harbouring the EGFR Exon 20 insertion mutation is platinum-based chemotherapy (CHT) (+/- immunotherapy) (NCCN Guidelines Version 5.2023, ESMO Clinical Practice Guideline on Oncogene-Addicted Metastatic NSCLC<sup>2</sup>). The response rates to immunotherapy regimens vary (0%–25%), depending on the specific EGFR exon 20 insertion mutation (NCCN Guidelines Version 5.2023). Reported median overall survival (OS) in patients with NSCLC harbouring EGFR Exon 20 insertion ranges from 17 – 30 months<sup>3,4</sup> and is therefore inferior to that in patients with the more common EGFR mutations Exon 19del and L858R, whose median OS reached 38.6 months in the pivotal trial FLAURA testing the current standard of care TKI treatment with osimertinib<sup>5</sup>. Reported median progression-free-survival ranges from 5.2 to 6.9 months<sup>Fehler! Textmarke nicht definiert.,Fehler! Textmarke nicht definiert.</sup>.

### 4 Nonclinical aspects

The applicant did not submit any new nonclinical studies to support the requested new indication, which is considered acceptable. From the nonclinical point of view, there are no objections to the approval of the requested new indication.

---

<sup>1</sup> Arcila ME et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther.* 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620.

<sup>2</sup> Hendriks LE et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol.* 2023 Apr;34(4):339-357.

<sup>3</sup> Ou SI et al. Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations. *JTO Clin Res Rep.* 2023 Aug 16;4(10):100558. doi: 10.1016/j.jtocrr.2023.100558.

<sup>4</sup> Leal JL, Alexander M, Itchins M, Wright GM, Kao S, Hughes BGM, Pavlakis N, Clarke S, Gill AJ, Ainsworth H, Solomon B, John T. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer.* 2021 Nov;22(6):e859-e869. doi: 10.1016/j.clcc.2021.04.009.

<sup>5</sup> Ramalingam SS et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med.* 2020 Jan 2;382(1):41-50.

## 5 Clinical aspects

### 5.1 Efficacy

The applicant has submitted the pivotal study PAPILLON to support the proposed indication. PAPILLON is an ongoing randomised, open-label phase 3 study in patients with EGFR exon 20 insertion (ins) mutated locally advanced or metastatic non-squamous NSCLC that were not treated for their advanced/metastatic disease. Patients were randomised 1:1 to either amivantamab + pemetrexed and carboplatin (experimental arm; ACP) or to pemetrexed and carboplatin alone (control arm; CP). The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR). Overall survival (OS) and objective response rate (ORR) were key secondary endpoints and multiplicity controlled.

At the data cut-off (DCO) on 03 May 2023 for the primary PFS analysis, the primary endpoint was met with a statistically significant prolongation of PFS in the ACP arm (median 11.4 vs 6.7 months, hazard ratio (HR) 0.395 95% CI 0.296, 0.528). The Kaplan-Meier (KM) curve for PFS indicates a long-term benefit in PFS of > 10% at 18 months. At the same DCO, results for the interim OS analysis were not yet significant with 18.3% (ACP arm) vs 27.1% (CP arm) OS events observed (HR 0.675, 95% CI 0.418, 1.090). The OS rate at 18 months (74% vs 68%) and at 24 months (72% vs 54%) was higher in the ACP arm. The KM curves for OS cross at about 8 months suggesting a numerically increased death rate (n=6), (3.9% vs. 0.6% in the ACP arm vs. CP, respectively) in the early phase after randomisation. With the answer to LOQ, no pattern for the reasons of early death was seen, and from 3 months onwards more patients died in the control arm. Although OS curves remain immature after 6 months the applicant provided additional prespecified analyses on OS that take into consideration the high cross-over rate (65 / 155 patients in the CP arm) from control to the (approved) Rybrevant in second line. In this inverse probability of censoring weight (IPCW) analysis, the OS HR was 0.52 (95% CI of 0.28; 0.94) supporting the primary endpoint and the OS ITT analyses. Final OS analyses are expected to occur in Q4 2025 and need to be submitted as a precondition for approval. Quality of life (QoL) was not compromised in the experimental arm compared to the control arm - rather, a longer median time to deterioration for certain symptoms of the EORTC-QLQ-C30 was reported in the ACP arm compared to the CP arm. Of note, all QoL analyses were descriptive.

### 5.2 Safety

Toxicity of the combination treatment with amivantamab + CHT is higher than with CHT alone, with a higher rate of grade 3-5 TEAEs (76% vs 54%), grade 5 TEAEs (4.6% vs 2.6%), TEAEs leading to discontinuation of any study drug (24% vs 10%), to dose reduction (48% vs 23%), and to dose interruption (69% vs 36%). As expected, adverse events of special interest (AESIs) were reported at a higher rate in the ACP arm: rash (89% vs 18%), infusion-related reactions (IRR) (42% vs 1%), and pneumonitis/interstitial lung disease (ILD) (2.6% vs 0).

For thromboembolic events, preferred terms such as pulmonary embolism, deep vein thrombosis, venous thrombosis limb, embolism, and thrombosis were all numerically higher in the experimental arm. This numerical increase of thromboembolic events is also seen in the Rybrevant-containing Mariposa and Mariposa 2 studies in patients with advanced and metastatic NSCLC.

In summary, the safety profile of amivantamab in combination with CHT was consistent with the safety profiles of the individual components, with manageable toxicity.

### 5.3 Final clinical benefit risk assessment

The combination of amivantamab and CHT is associated with a statistically significant improvement in PFS of 4.7 months along with a long-term benefit in PFS of > 10% at 18 months. With the immature OS data at hand, a non-statistical positive trend in favour of the experimental arm is observed despite a high cross-over rate of patients in the control arm to receive Rybrevant in second line.

Additional prespecified OS analyses adjusting for the cross-over of patients in the control arm to receive Rybrevant in second line showed a consistent, favourable effect in favour of the experimental arm.

The safety profile of ACP added toxicity as compared to CP but is manageable in the hands of experienced oncologists and did not appear to compromise the QoL of patients.

In conclusion, the benefit-risk is positive for an approval without specific condition (regular approval).

## 6 Risk management plan summary

The RMP summaries contain information on the medicinal products' safety profiles and explain the measures that are taken to further investigate and monitor the risks, as well as to prevent or minimise them.

The RMP summaries are published separately on the Swissmedic website. It is the responsibility of the marketing authorisation holder to ensure that the content of the published RMP summaries is accurate and correct. As the RMPs are international documents, their summaries might differ from the content in the Information for healthcare professionals / product information approved and published in Switzerland, e.g. by mentioning risks that occur in populations or indications not included in the Swiss authorisations.

## 7 Appendix

### Approved Information for healthcare professionals

Please be aware that the following version of the Information for healthcare professionals for Rybrevant was approved with the submission described in the SwissPAR. This Information for healthcare professionals may have been updated since the SwissPAR was published.

Please note that the valid and relevant reference document for the effective and safe use of medicinal products in Switzerland is the Information for healthcare professionals currently authorised by Swissmedic (see [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch)).

#### **Note:**

The following Information for healthcare professionals has been translated by the MAH. It is the responsibility of the authorisation holder to ensure the translation is correct. The only binding and legally valid text is the Information for healthcare professionals approved in one of the official Swiss languages.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected new or serious adverse reactions. See the "Undesirable effects" section for advice on the reporting of adverse reactions.

### **RYBREVANT<sup>®</sup>, concentrate for solution for infusion**

#### **Composition**

##### *Active substances*

Amivantamab.

Amivantamab is an immunoglobulin G1 [IgG1]-based bispecific antibody produced in Chinese Hamster Ovary [CHO] cells using recombinant DNA technology.

##### *Excipients*

Disodium edetate, L-Histidine, L-Histidine hydrochloride monohydrate, L-Methionine, Polysorbate 80, Sucrose, Water for Injection.

Total sodium content: 17 µg/7 ml.

#### **Pharmaceutical form and active substance quantity per unit**

Concentrate for solution for infusion. The solution is colourless to pale yellow.

Each vial contains 350 mg of amivantamab per 7 mL (50 mg of amivantamab per mL).

#### **Indications/Uses**

RYBREVANT is indicated

- in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations (see "Clinical Efficacy").
- in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitutions mutations, whose disease has progressed on or after treatment with Osimertinib (see "Clinical Efficacy").
- as monotherapy for the treatment of patients with metastatic or unresectable NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-containing chemotherapy.

#### **Dosage/Administration**

RYBREVANT should be administered by a healthcare professional with appropriate medical support to manage infusion-related reactions (IRRs) if they occur (see "Warnings and Precautions").

Administer pre-infusion medications (see "Dosage / Administration" – Pre-infusion Medications).

Administer diluted RYBREVANT intravenously according to the infusion rates in Tables 3 and 4, with the initial dose as a split infusion on Week 1 on Day 1 and Day 2.

If a positive EGFR mutation status is determined using a validated plasma or tissue-based test, the patient is suitable for treatment with RYBREVANT (see “Pharmacodynamics - Clinical efficacy”).

It is recommended that patients are treated with RYBREVANT until disease progression or unacceptable toxicity.

To ensure traceability of biotechnological medicinal products, it is recommended that the trade name and batch number should be documented for each treatment.

*Usual dosage - Adults (≥18 years)*

*RYBREVANT in combination with carboplatin and pemetrexed*

The recommended dosage of RYBREVANT, when used in combination with 4 cycles of carboplatin and pemetrexed, and afterwards continued in combination with pemetrexed until disease progression or toxicity, is provided in Table 1 (Infusion Rates – see Table 3).

**Table 1: Recommended Dose and 3-week Dosing Schedule for RYBREVANT**

<b>Body weight at Baseline<sup>a</sup></b>	<b>RYBREVANT Dose</b>	<b>Schedule</b>
Less than 80 kg	1400 mg	Weekly (total of 4 doses) from Weeks 1 to 4 <ul style="list-style-type: none"> <li>• Week 1 - split infusion on Day 1 and Day 2</li> <li>• Weeks 2 to 4 - infusion on Day 1</li> </ul>
	1750 mg	Every 3 weeks starting at Week 7 onwards
Greater than or equal to 80 kg	1750 mg	Weekly (total of 4 doses) for Weeks 1 to 4 <ul style="list-style-type: none"> <li>• Week 1 - split infusion on Day 1 and Day 2</li> <li>• Weeks 2 to 4 - infusion on Day 1</li> </ul>
	2100 mg	Every 3 weeks starting at Week 7 onwards
<sup>a</sup> Dose adjustments not required for subsequent body weight changes.		

When used in combination with carboplatin and pemetrexed, RYBREVANT should be administered after carboplatin and pemetrexed in the following order: pemetrexed, carboplatin and then RYBREVANT. See “Clinical Efficacy” and the manufacturer’s prescribing information for dosing instructions for carboplatin and pemetrexed.

*Monotherapy*

The recommended dosage of RYBREVANT monotherapy is provided in Table 2 (Infusion Rates – see Table 4).

**Table 2: Recommended Dose and 2-week Dosing Schedule for RYBREVANT**

Body weight at Baseline <sup>a</sup>	Recommended Dose	Dosing Schedule
Less than 80 kg	1050 mg	Weekly (total of 4 doses) from Weeks 1 to 4 <ul style="list-style-type: none"> <li>• Week 1 - split infusion on Day 1 and Day 2</li> <li>• Weeks 2 to 4 - infusion on Day 1</li> </ul>
		Every 2 weeks starting at Week 5 onwards
Greater than or equal to 80 kg	1400 mg	Weekly (total of 4 doses) from Weeks 1 to 4 <ul style="list-style-type: none"> <li>• Week 1 - split infusion on Day 1 and Day 2</li> <li>• Weeks 2 to 4 - infusion on Day 1</li> </ul>
		Every 2 weeks starting at Week 5 onwards

<sup>a</sup> Dose adjustments not required for subsequent body weight changes.

### Infusion Rates

Administer RYBREVANT infusion every 3 weeks intravenously according to the infusion rates in Table 3 and administer RYBREVANT infusion every 2 weeks intravenously according to the infusion rates in Table 4.

Due to the frequency of IRRs at the first dose, infusion via a peripheral vein at Week 1 and Week 2 should be considered to minimize drug exposure in the event of an IRR; infusion via central line may be administered for subsequent weeks (from week 3). It is recommended for the first dose to be diluted as close to administration as possible to allow for maximal flexibility in IRR management.

**Table 3: Infusion Rates for RYBREVANT Every 3 Weeks**

Body Weight Less than 80 kg			
Week	Dose (per 250 mL bag)	Initial Infusion Rate	Subsequent Infusion Rate <sup>†</sup>
Week 1 (split dose infusion)			
Week 1 Day 1	350 mg	50 mL/hr	75 mL/hr
Week 1 Day 2	1050 mg	33 mL/hr	50 mL/hr
Week 2	1400 mg	65 mL/hr	
Week 3	1400 mg	85 mL/hr	
Week 4	1400 mg	125 mL/hr	
Subsequent weeks*	1750 mg	125 mL/hr	
Body Weight Greater Than or Equal to 80 kg			
Week	Dose (per 250 mL bag)	Initial Infusion Rate	Subsequent Infusion Rate
Week 1 (split dose infusion)			
Week 1 Day 1	350 mg	50 mL/hr	75 mL/hr
Week 1 Day 2	1400 mg	25 mL/hr	50 mL/hr
Week 2	1750 mg	65 mL/hr	
Week 3	1750 mg	85 mL/hr	

Week 4	1750 mg	125 mL/hr
Subsequent weeks*	2100 mg	125 mL/hr

\* Starting at Week 7, patients are dosed every 3 weeks.

† Increase the initial infusion rate to the subsequent infusion rate after 2 hours in the absence of infusion-related reactions.

Table 4: Infusion Rates for RYBREVANT Every 2 Weeks

Body Weight Less Than 80 kg			
Week	Dose (per 250 mL bag)	Initial Infusion Rate	Subsequent Infusion Rate†
Week 1 (split dose infusion)			
Week 1 Day 1	350 mg	50 mL/hr	75 mL/hr
Week 1 Day 2	700 mg	50 mL/hr	75 mL/hr
Week 2	1050 mg	85 mL/hr	
Subsequent weeks*	1050 mg	125 mL/hr	
Body Weight Greater Than or Equal to 80 kg			
Week	Dose (per 250 mL bag)	Initial Infusion Rate	Subsequent Infusion Rate
Week 1 (split dose infusion)			
Week 1 Day 1	350 mg	50 mL/hr	75 mL/hr
Week 1 Day 2	1050 mg	35 mL/hr	50 mL/hr
Week 2	1400 mg	65 mL/hr	
Week 3	1400 mg	85 mL/hr	
Subsequent weeks*	1400 mg	125 mL/hr	

\* As of Week 5, patients are dosed every 2 weeks.

† Increase the initial infusion rate to the subsequent infusion rate after 2 hours in the absence of infusion-related reactions.

### Pre-infusion medications

Prior to initial infusion of RYBREVANT (Week 1, Days 1 and 2), administer antihistamines, antipyretics, and glucocorticoids to reduce the risk of IRRs (see table 5). As of week 2, administer antihistamines and antipyretics (see table 5). Administer antiemetics as needed.

Table 5: Pre-Medications

Medication	Dose	Route of Administration	Dosing Window Prior to RYBREVANT Administration
Antihistamine*		IV	15 to 30 minutes

Table 5: Pre-Medications

Medication	Dose	Route of Administration	Dosing Window Prior to RYBREVANT Administration
	Diphenhydramine (25 to 50 mg) or equivalent	Oral	30 to 60 minutes
Antipyretic*	Paracetamol/Acetaminophen (650 to 1000 mg) or equivalent	IV	15 to 30 minutes
		Oral	30 to 60 minutes
Glucocorticoid‡	Dexamethasone (20 mg) or equivalent	IV	60 to 120 minutes
Glucocorticoid+	Dexamethasone (10 mg) or equivalent	IV	45 to 60 minutes

\* Required at all doses.

‡ Required at initial dose (Week 1, Day 1).

+ Required at second dose (Week 1, Day 2); optional for subsequent doses.

**Dose adjustment following undesirable effects**

The recommended dose reductions for adverse reactions (see Table 7) are listed in Table 6.

Table 6: RYBREVANT Dose Reductions for Adverse Reactions

Dose*	1 <sup>st</sup> Dose Reduction	2 <sup>nd</sup> Dose Reduction	3 <sup>rd</sup> Dose Modification
1050 mg	700 mg	350 mg	Discontinue RYBREVANT
1400 mg	1050 mg	700 mg	
1750 mg	1400 mg	1050 mg	
2100 mg	1750 mg	1400 mg	

\* Dose at which the adverse reaction occurred

The recommended dosage modifications for adverse reactions are provided in Table 7.

Table 7: RYBREVANT Dosage Modifications for Adverse Reactions

Adverse Reaction	Severity	Dose Modification
Infusion-Related Reactions (IRR) (see “Warnings and Precautions”)	Grade 1 to 3	<ul style="list-style-type: none"> <li>Interrupt infusion at the first sign of IRRs.</li> <li>Additional supportive medications (e.g., additional glucocorticoids, antihistamine, antipyretics and antiemetics) should be administered as clinically indicated.</li> <li>Upon resolution of symptoms, resume infusion at 50% of the previous rate.</li> <li>If there are no additional symptoms, the rate may be increased per the recommended infusion rate (see Tables 3 and 4).</li> </ul>

## Information for healthcare professionals

		<ul style="list-style-type: none"> <li>• Pre-medications should be administered prior to the next dose (see Table 5).</li> </ul>
	Recurrent Grade 3 or Grade 4 (life-threatening)	Permanently discontinue.
<i>Interstitial Lung Disease (ILD)/ Pneumonitis</i> (see “Warnings and Precautions”)	Suspected ILD/ pneumonitis	Withhold.
	Confirmed ILD/ pneumonitis	Permanently discontinue.
<i>Skin and Nail Reactions</i> (see “Warnings and Precautions”)	Grade 1	<ul style="list-style-type: none"> <li>• Supportive care should be initiated.</li> <li>• Reassess after 2 weeks.</li> </ul>
	Grade 2	<ul style="list-style-type: none"> <li>• Supportive care should be initiated.</li> <li>• If there is no improvement after 2 weeks, consider reducing the dose (see Table 6).</li> </ul>
	Grade 3	<ul style="list-style-type: none"> <li>• Supportive care should be initiated.</li> <li>• Withhold until the adverse reaction improves to <math>\leq</math> Grade 2.</li> <li>• Resume at reduced dose (see Table 6).</li> </ul>
	Grade 4 (including severe bullous, blistering or exfoliating skin conditions (including toxic epidermal necrolysis (TEN)))	Permanently discontinue.
<i>Other Adverse Reactions</i> (see “Adverse Reactions”)	Grade 3	<ul style="list-style-type: none"> <li>• Withhold until adverse reaction improves to <math>\leq</math> Grade 1 or baseline.</li> <li>• Resume at same dose if recovery occurs within 1 week.</li> <li>• Resume at reduced dose (see Table 6) if recovery occurs after 1 week.</li> <li>• Permanently discontinuing if recovery does not occur within 4 weeks.</li> </ul>
	Grade 4	<ul style="list-style-type: none"> <li>• Withhold until adverse reaction improves to <math>\leq</math> Grade 1 or baseline.</li> <li>• Resume at reduced dose (see Table 6) if recovery occurs within 4 weeks.</li> <li>• Permanently discontinuing if recovery does not occur within 4 weeks.</li> </ul>

### *Special dosage instructions*

#### *Patients with hepatic disorders*

No formal studies of amivantamab in patients with hepatic impairment have been conducted. Based on population PK analyses, no dosage adjustment is necessary for patients with mild hepatic impairment. No data are available in patients with moderate or severe hepatic impairment (see “Pharmacokinetics”).

#### *Patients with renal disorders*

No formal studies of amivantamab in patients with renal impairment have been conducted. Based on population pharmacokinetic (PK) analyses, no dosage adjustment is necessary for patients with mild or moderate renal impairment. No data are available in patients with severe renal impairment (see “Pharmacokinetics”).

#### *Elderly patients*

Of the 661 patients treated with RYBREVANT in EDI1001 (CHRYSALIS), NSC3001 (PAPILLON) and NSC3002 (MARIPOSA-2), 40% were 65 years of age or older, and 10% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. No dosage adjustment is necessary (see “Pharmacokinetics”).

#### *Children and adolescents (17 years of age and younger)*

The safety and efficacy of RYBREVANT have not been established in pediatric patients.

#### *Delayed administration*

If a planned dose of RYBREVANT is missed, the dose should be administered as soon as possible and the dosing schedule should be adjusted accordingly, maintaining the treatment interval.

### **Contraindications**

Hypersensitivity to the active substance or to any of the excipients according to the composition.

### **Warnings and precautions**

#### *Venous Thromboembolic Events (VTE)*

In patients treated with RYBREVANT as monotherapy or in combination with chemotherapy or Lazertinib, VTE (e.g. deep vein thrombosis and pulmonary embolism), including serious and fatal events, may occur (see “Undesirable Effects”).

Patients should be monitored for signs and symptoms of VTE and treated as medically appropriate.

#### *Infusion-Related Reactions (IRR)*

Infusion-related reactions may occur in patients treated with RYBREVANT.

Infusion-related reactions occurred in 61% of patients treated with RYBREVANT. 93% of IRRs were Grade 1-2. A majority of IRRs occurred at the first infusion with a median time to onset of 60 minutes. The most frequent signs and symptoms include chills, nausea, dyspnea, flushing, chest discomfort, and vomiting.

Prior to initial infusion (Week 1) of RYBREVANT, administer antihistamines, antipyretics, and glucocorticoids to reduce the risk of IRRs. For subsequent doses, administer antihistamines and antipyretics. Administer the initial infusion of RYBREVANT in split doses on Week 1, Days 1 and 2. (see “Dosage / Administration”).

Treat patients with RYBREVANT in a setting with appropriate medical support necessary to treat IRRs. Interrupt RYBREVANT infusion at the first sign of IRRs and institute post-infusion medication (glucocorticoids, antihistamines, antipyretics) as clinically indicated. Upon resolution of symptoms, resume the infusion at 50% of the previous rate. For recurrent Grade 3 or 4 IRRs, permanently discontinue RYBREVANT (see “Dosage / Administration”).

### *Interstitial Lung Disease (ILD/Pneumonitis)*

Interstitial lung disease (ILD) or ILD-like adverse reactions (e.g. pneumonitis) occurred in 2.7% of patients treated with RYBREVANT, with Grade 3 or 4 ILD occurring in 1.1% of patients and one fatal case (0.1%) (see “Undesirable Effects”). Adverse reactions related to ILD leading to treatment discontinuation occurred in 1.8% of patients. Patients with a medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD have not been studied.

Monitor patients for symptoms indicative of ILD/pneumonitis (e.g. dyspnea, cough, fever). If symptoms develop, interrupt treatment with RYBREVANT pending investigation of these symptoms. Evaluate suspected ILD and initiate appropriate treatment as necessary. Discontinue RYBREVANT in patients with confirmed ILD (see “Dosage / Administration” and “Undesirable Effects”).

### *Skin and Nail Reactions*

Skin and nail reactions may occur in patients treated with RYBREVANT.

Rash (including dermatitis acneiform), pruritus and dry skin occurred in patients treated with RYBREVANT. Most cases were Grade 1 or 2, with Grade 3 events occurring in 15.5% of patients. Rash leading to RYBREVANT discontinuation occurred in 2.9% of patients. Rash usually developed within the first 4 weeks of therapy, with a median time to onset of 14 days. Toxic epidermal necrolysis (TEN) has been reported. Permanently discontinue RYBREVANT if TEN is confirmed. Nail toxicity occurred in patients treated with RYBREVANT. Most events were Grade 1 or 2, with Grade 3-4 nail toxicity occurring in 6.3% of patients.

A prophylactic approach to rash preventions should be considered. Instruct patients to limit sun exposure during and for 2 months after RYBREVANT therapy. Protective clothing and use of sunscreen is advisable. Alcohol-free emollient cream is recommended for dry areas with the use of

RYBREVANT. If skin or nail reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 events, administer systemic antibiotics and oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. Withhold, dose reduce or permanently discontinue RYBREVANT based on severity (see “Dosage / Administration”).

### *Eye Disorders*

Eye disorders, including keratitis (1.3%), occurred in patients treated with RYBREVANT. Other reported adverse reactions included dry eye, blurred vision, eye pruritus, visual impairment, aberrant eyelash growth, ocular hyperemia, conjunctival hyperemia, blepharitis and uveitis. Most events were Grade 1-2, Grade 3-4 keratitis events were observed in 0.2 % of patients. Refer patients presenting with new eye symptoms or worsening eye symptoms promptly to an ophthalmologist and advise discontinuation of contact lenses until symptoms are evaluated.

### *Excipients*

RYBREVANT contains less than 1 mmol sodium (23 mg) per 1 vial, i.e. it is almost "sodium-free".

### **Interactions**

No drug interaction studies have been performed.

### **Pregnancy, lactation**

#### *Women of childbearing age*

Due to the risk that RYBREVANT can cause fetal harm when administered to pregnant women, advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT.

#### *Pregnancy*

There are no human or animal data to assess the risk of RYBREVANT in pregnancy. Administration of other EGFR and MET inhibitor molecules to pregnant animals has resulted in an increased incidence of impairment of embryo-fetal development, embryo lethality, and abortion. Therefore, based on its mechanism of action and findings in animal models, RYBREVANT could cause fetal harm when administered to a pregnant woman.

RYBREVANT must not be used during pregnancy unless the treatment with RYBREVANT is necessary because of the woman's clinical condition. If the patient becomes pregnant while taking this drug, the patient should be informed of the potential risk to the fetus.

#### *Lactation*

It is not known whether RYBREVANT is excreted in human or animal milk or affects milk production. Because of the potential for serious adverse reactions from RYBREVANT in breast-fed infants, advise

women not to breast-feed during treatment with RYBREVANT and for 3 months following the last dose of RYBREVANT.

### *Fertility*

No data are available to determine potential effects of RYBREVANT on fertility in males or females.

### **Effects on ability to drive and use machines**

RYBREVANT may have moderate influence on the ability to drive and use machines (see section “Undesirable effects” (e.g., dizziness, fatigue, visual impairment)). If patients experience treatment-related symptoms, including vision-related adverse reactions, affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

### **Undesirable effects**

The safety data below reflect exposure to RYBREVANT in 1082 patients with locally advanced or metastatic NSCLC, including 380 patients who received RYBREVANT monotherapy in Study EDI1001 (CHRYSLIS), 151 patients who received RYBREVANT in combination with carboplatin and pemetrexed in Study NSC3001 (PAPILLON), 130 patients who received RYBREVANT in combination with carboplatin and pemetrexed in Study NSC3002 (MARIPOSA-2) and 421 patients who received RYBREVANT in combination with lazertinib in Study NSC3003 (MARIPOSA). Patients received RYBREVANT until disease progression or unacceptable toxicity.

The most common adverse reactions ( $\geq 20\%$ ) were rash (82%), IRR (61%), nail toxicity (58%), hypoalbuminemia (38%), oedema (37%), stomatitis (36%), fatigue (32%), constipation (30%), nausea (27%), decreased appetite (24%), increased alanine aminotransferase (26%), increased aspartate aminotransferase (22%) and venous thromboembolism (21%). The most common grade 3-4 events were venous thromboembolism (6.6%), rash (15.5%) and nail toxicity (6.3%). Serious adverse reactions included VTE (5.8%), ILD (2.1%), IRR (1.5%) and rash (2%). 12% of patients discontinued RYBREVANT due to adverse reactions. The most frequent adverse reaction leading to treatment discontinuation were IRR (2.9%), ILD (1.9%), nail toxicity (1.9%) and rash (2.9%).

Table 8 presents adverse reactions reported in patients treated with RYBREVANT in studies EDI1001, NSC3001, NSC3002 and NSC3003.

Adverse reactions are listed by system organ class and frequency: very common ( $\geq 1/10$ ), common ( $\geq 1/100$ ,  $< 1/10$ ), uncommon ( $\geq 1/1000$ ,  $< 1/100$ ), and rare ( $\geq 1/10,000$ ,  $< 1/1000$ ), very rare ( $< 1/10,000$ ) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

*Table 8: Adverse Reactions in Patients with NSCLC, who were treated with RYBREVANT in the studies EDI1001, NSC3001, NSC3002 and NSC3003 (N=1082)*

## Information for healthcare professionals

System Organ Class Frequency Category	Adverse Reaction
<i>Blood and lymphatic system disorders</i>	
Very common	Neutropenia* (58%), Thrombocytopenia* (40%)
<i>Metabolism and nutrition disorders</i>	
Very common	Hypoalbuminaemia <sup>a</sup> (38%), Decreased appetite (24%), Hypocalcaemia (15%), Hypokalaemia (14%)
Common	Hypomagnesaemia
<i>Nervous system disorders</i>	
Very common	Dizziness <sup>b</sup> (12%)
<i>Eye disorders</i>	
Very common	Other eye disorders <sup>c</sup> (14%)
Common	Visual impairment <sup>d</sup> , Keratitis, Growth of eyelashes <sup>e</sup>
Uncommon	Uveitis
<i>Vascular disorders</i>	
Very common	Venous thromboembolism <sup>f</sup> (21%)
<i>Respiratory, thoracic and mediastinal disorders</i>	
Common	Interstitial lung disease <sup>g</sup>
<i>Gastrointestinal disorders</i>	
Very common	Stomatitis <sup>h</sup> (36%), Constipation (30%), Nausea (27%), Diarrhoea (20%), Vomiting (15%), Abdominal pain <sup>i</sup> (10%)
Common	Haemorrhoids
<i>Hepatobiliary disorders</i>	
Very common	Alanine aminotransferase increased (26%), Aspartate aminotransferase increased (22%), Blood alkaline phosphatase increased (13%)
<i>Skin and subcutaneous tissue disorders</i>	
Very common	Rash <sup>j</sup> (82%), Nail toxicity <sup>k</sup> (58%), Dry skin <sup>l</sup> (21%), Pruritus (18%)
Uncommon	Toxic epidermal necrolysis
<i>Musculoskeletal and connective tissue disorders</i>	
Very common	Myalgia
<i>General disorders and administration site conditions</i>	

Very common	Oedema <sup>m</sup> (37%), Fatigue <sup>n</sup> (32%), Pyrexia (12%)
<i>Injury, poisoning and procedural complications</i>	
Very common	Infusion related reaction (61%)

\*only in combination with chemotherapy (n=281)

a Blood albumin decreased, Hypoalbuminaemia

b Dizziness, Dizziness exertional, Vertigo

c Blepharitis, Conjunctival hyperaemia, Conjunctivitis, Corneal irritation, Dry eye, Episcleritis, Eye disorder, Eye pruritus, Noninfective conjunctivitis, Ocular hyperaemia

d Vision blurred, Visual acuity reduced, Visual impairment

e Growth of eyelashes, Trichomegaly

f Axillary vein thrombosis, Deep vein thrombosis, Embolism, Embolism venous, Jugular vein thrombosis, Portal vein thrombosis, Pulmonary embolism, Pulmonary infarction, Sigmoid sinus thrombosis, Superior sagittal sinus thrombosis, Thrombosis, Vena cava thrombosis, Venous thrombosis, Venous thrombosis limb

g Interstitial lung disease, Pneumonitis

h Angular cheilitis, Aphthous ulcer, Cheilitis, Glossitis, Lip ulceration, Mouth ulceration, Mucosal inflammation, Stomatitis

i Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Epigastric discomfort, Gastrointestinal pain

j Acne, Dermatitis, Dermatitis acneiform, Erythema, Erythema multiforme, Folliculitis, Impetigo, Palmar-plantar erythrodysesthesia syndrome, Perineal rash, Perioral dermatitis, Pustule, Rash, Rash erythematous, Rash follicular, Rash macular, Rash maculo-papular, Rash papular, Rash pruritic, Rash pustular, Rash vesicular, Skin exfoliation, Skin lesion

k Ingrowing nail, Nail bed disorder, Nail bed infection, Nail bed inflammation, Nail cuticle fissure, Nail disorder, Nail dystrophy, Nail infection, Nail ridging, Nail toxicity, Onychoclasia, Onycholysis, Onychomadesis, Paronychia

l Dry skin, Eczema, Eczema asteatotic, Skin fissures, Xeroderma, Xerosis

m Eye oedema, Eyelid oedema, Face oedema, Generalised oedema, Localised oedema, Oedema, Oedema peripheral, Periorbital oedema, Periorbital swelling, Peripheral swelling, Swelling face

n Asthenia, Fatigue

### *Venous Thromboembolic Events (VTE)*

In patients treated with RYBREVANT as monotherapy or in combination with chemotherapy or Lazertinib, VTE, including deep vein thrombosis and pulmonary embolism, occurred in 20.6% of patients including Grade 3-4 in 6.6% of patients. Two fatal cases of VTEs have also been reported in patients treated with RYBREVANT in combination with Lazertinib.

In patients treated with RYBREVANT in combination with chemotherapy, VTE occurred in 13.2% patients including Grade 3 in 2.8%.

### *Infusion-related reactions*

Infusion-related reactions occurred in 61% of patients treated with RYBREVANT. 93% of IRRs were Grade 1-2. 80% of IRRs occurred at the first infusion with a median time to onset of 60 minutes. The most frequent signs and symptoms include chills, nausea, dyspnea, flushing, chest discomfort, and vomiting.

After a prolonged dose interruption of more than 6 weeks, an IRR may occasionally occur when resuming treatment with RYBREVANT.

### *Interstitial lung disease*

Interstitial lung disease or ILD-like adverse reactions have been reported with the use of RYBREVANT as well as with other EGFR inhibitors. Interstitial lung disease or pneumonitis were reported in 2.7% patients treated with RYBREVANT, with Grade 3-4 events occurring in 1.1% of patients and one fatal case (0.1%) (see “Warnings and Precautions”). Adverse events leading to discontinuation occurred in 1.8% of patients.

### *Skin and nail reactions*

Rash (including dermatitis acneiform) occurred in 82% patients treated with amivantamab. Most cases were Grade 1 or 2, with Grade 3-4 rash events occurring in 15.5% of patients. Rash leading to amivantamab discontinuation occurred in 2.9% of patients. Rash usually developed within the first 4 weeks of therapy, with a median time to onset of 14 days. Nail toxicity occurred in patients treated with amivantamab. Most events were Grade 1 or 2, with Grade 3-4 nail toxicity occurring in 6.3% of patients.

### *Eye disorders*

Eye disorders, including keratitis (1.3%), occurred in patients treated with amivantamab. Other reported adverse reactions included dry eye, blurred vision, eye pruritus, visual impairment, aberrant eyelash growth, ocular hyperemia, conjunctival hyperemia, blepharitis and uveitis. Most events were Grade 1-2, Grade 3-4 keratitis events were observed in 0.2 % of patients.

Reporting suspected adverse reactions after authorisation of the medicinal product is very important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions online via the EIViS portal (Electronic Vigilance System). You can obtain information about this at [www.swissmedic.ch](http://www.swissmedic.ch).

### **Overdose**

#### *Signs and symptoms*

There is no information on overdosage with RYBREVANT. There has been no experience of overdosage in clinical studies. No maximum tolerated dose has been determined in a clinical study in which patients received up to 1750 mg administered intravenously.

#### *Treatment*

There is no known specific antidote for RYBREVANT overdose. In the event of an overdose, stop RYBREVANT, undertake general supportive measures until clinical toxicity has diminished or resolved.

### **Properties/Effects**

#### *ATC code*

L01FX18

#### *Mechanism of action*

Amivantamab is a low-fucose, fully-human IgG1-based EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. Amivantamab binds to the extracellular domains of EGFR and MET. Preclinical studies show amivantamab is active against tumors with primary EGFR activating mutations like Exon 19 deletions, L858R substitutions and Exon 20 insertion mutations. Amivantamab disrupts EGFR and MET signaling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumor growth and progression. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.

#### *Pharmacodynamics*

##### *Albumin*

Amivantamab decreased serum albumin concentration, a pharmacodynamic effect of MET inhibition, typically during the first 8 weeks; thereafter, albumin concentration stabilized for the remainder of amivantamab treatment.

##### *Immunogenicity*

As with all therapeutic proteins, there is the potential for immunogenicity also for amivantamab. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample

collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in different studies may be misleading.

In clinical trials of patients with locally advanced or metastatic NSCLC as monotherapy or as part of a combination therapy, 4 of the 1078 (0.4%) participants who were treated with RYBREVANT and evaluable for the presence of anti-drug antibodies (ADA), tested positive for treatment-emergent anti-amivantamab antibodies. No evident effect of immunogenicity on efficacy, and safety events (including IRRs) has been observed.

### *Clinical efficacy*

#### *Previously Untreated NSCLC*

##### *Previously untreated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations*

NSC3001 (PAPILLON) is a randomized, open-label, multicenter phase 3 study comparing treatment with RYBREVANT in combination with carboplatin and pemetrexed versus chemotherapy alone (carboplatin and pemetrexed) in adult subjects with treatment-naïve, locally advanced or metastatic non-squamous NSCLC with EGFR Exon 20 insertion mutations. Tumor tissue (92.2%) and/or plasma samples (7.8%) for all 308 patients were tested locally to determine EGFR Exon 20 insertion mutation status using Next Generation Sequencing (NGS) in 55.5% of patients and/or polymerase chain reaction (PCR) in 44.5% of patients.

Patients with brain metastases at screening were eligible for participation once they were definitively treated, clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization. Patients with a medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD were excluded from the clinical study. (Neo)adjuvant platinum-based doublet chemotherapy was permitted if completed 12 months prior.

RYBREVANT was administered intravenously at 1400 mg (for subjects < 80 kg) or 1750 mg (for subjects ≥ 80 kg) once weekly through 4 weeks, then every 3 weeks with a dose of 1750 mg (for patients < 80 kg) or 2100 mg (for subjects ≥ 80 kg) starting at Week 7 until disease progression or unacceptable toxicity. Carboplatin was administered intravenously at area under the concentration-time curve 5 mg/mL per minute (AUC 5) once every 3 weeks, for up to 12 weeks. Pemetrexed was administered intravenously at 500 mg/m<sup>2</sup> once every 3 weeks until disease progression or unacceptable toxicity. Randomization was stratified by ECOG performance status and prior brain metastases. Subjects randomized to the carboplatin and pemetrexed arm who had confirmed disease progression were permitted to cross over to receive RYBREVANT monotherapy.

A total of 308 subjects were randomized (1:1) to RYBREVANT in combination with carboplatin and pemetrexed (N=153) or carboplatin and pemetrexed (N=155). The median age was 62 (range: 27 to 92) years, with 39% of the subjects ≥ 65 years of age; 58% were female; and 61% were Asian and 36% were White. Baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0

(35%) or 1 (65%); 58% never smoked; 23% had history of brain metastasis and 84% had Stage IV cancer at initial diagnosis.

RYBREVANT in combination with carboplatin and pemetrexed demonstrated a statistically significant improvement in progression-free survival (PFS) compared to carboplatin and pemetrexed, with a HR of 0.40 (95% CI: 0.30, 0.53;  $p < 0.0001$ ). At the time of primary analysis, there were 28 deaths occurring in the RYBREVANT + carboplatin + pemetrexed arm and 42 deaths in the carboplatin + pemetrexed arm. A greater proportion of patients treated with RYBREVANT in combination with carboplatin and pemetrexed were alive at 18 and 24 months (74% and 72%, respectively) compared to patients treated with carboplatin and pemetrexed (68% and 54%, respectively). Overall survival showed no statistically significant difference between treatment arms (at 44% of pre-specified deaths for the final analysis reported). 65 subjects (42%) who were randomized to receive carboplatin and pemetrexed crossed over to receive RYBREVANT monotherapy.

Efficacy results for Study 3001 are summarized in Table 9.

Table 9: Efficacy Results in Study 3001

	<b>RYBREVANT + carboplatin + pemetrexed (N=153)</b>	<b>carboplatin + pemetrexed (N=155)</b>
<b>Progression-free survival (PFS)<sup>a</sup></b>		
Number of events (%)	84 (55%)	132 (85%)
Median, months (95% CI)	11.4 (9.8, 13.7)	6.7 (5.6, 7.3)
HR (95% CI); p-value	0.40 (0.30, 0.53); $p < 0.0001$	
<b>Objective response rate<sup>a</sup></b>		
ORR, % (95% CI)	73% (65%, 80%)	47% (39%, 56%)
Odds ratio (95% CI); p-value	3.0 (1.8, 4.8); $p < 0.0001$	
Complete response	3.9%	0.7%
Partial response	69%	47%
<b>Duration of response (DOR)<sup>a†</sup></b>		
Median <sup>b</sup> (95% CI), months	10.1 (8.5, 13.9)	5.6 (4.4, 6.9)
Patients with DOR $\geq$ 6 months	77%	44%
Patients with DOR $\geq$ 12 months	45%	11%

CI = confidence interval

<sup>a</sup> Blinded Independent Central Review by RECIST v1.1

<sup>b</sup> Based on the results of interim analysis of OS. The OS analysis was not adjusted for the potentially confounding effects of crossover (65 [42%] patients on the carboplatin + pemetrexed arm who received subsequent RYBREVANT monotherapy treatment).

<sup>‡</sup> In confirmed responders.

### *Previously Treated NSCLC*

#### *Previously Treated NSCLC Patients with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations*

The efficacy of RYBREVANT was evaluated in patients with locally advanced or metastatic non-squamous NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations (characterized by a validated test at or after the time of locally advanced or metastatic disease diagnosis, as identified by local or central testing) in a randomized (2:2:1), open-label, multicenter phase 3 clinical trial (MARIPOSA-2). Included patients had to demonstrate progression during or after osimertinib monotherapy. In MARIPOSA-2, patients received carboplatin and pemetrexed (CP, N=263) or RYBREVANT in combination with carboplatin and pemetrexed (RYBREVANT-CP, N=131) or RYBREVANT in combination with lazertinib, carboplatin and pemetrexed (an unapproved treatment for NSCLC). RYBREVANT was administered intravenously at 1,400 mg (for patients < 80 kg) or 1,750 mg (for patients ≥ 80 kg) once weekly for 4 weeks, then every 3 weeks with a dose of 1,750 mg (for patients < 80 kg) or 2,100 mg (for patients ≥ 80 kg) starting at Week 7 until disease progression or unacceptable toxicity. Carboplatin was administered intravenously at area under the concentration-time curve 5 mg/mL per minute (AUC 5) once every 3 weeks, for up to 12 weeks. Pemetrexed was administered intravenously at 500 mg/m<sup>2</sup> on once every 3 weeks until disease progression or unacceptable toxicity.

Patients were stratified by osimertinib line of therapy (first-line or second-line), prior brain metastases (yes or no), and Asian race (yes or no).

The primary efficacy endpoint was progression-free survival (PFS) by BICR. Other efficacy endpoints were overall survival (OS) and objective response rate (ORR).

Of the 394 patients randomized to the RYBREVANT-CP arm or CP arm, the median age was 62 (range: 31–85) years, with 37.8% of the patients ≥ 65 years of age; 60.4% were female; and 48.2% were Asian and 46.4% were White. Baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 (39.6%) or 1 (60.4%); 65.5% never smoked; 45.2% had history of brain metastasis, 0.9% had Stage III cancer at screening stage and 99.1% had Stage IV cancer at screening stage.

RYBREVANT in combination with carboplatin and pemetrexed demonstrated in the primary analysis of PFS (data cut-off July 2023) a statistically significant improvement in progression-free survival

(PFS) compared to carboplatin and pemetrexed, with a HR of 0.48 (95% CI: 0.36, 0.64;  $p < 0.0001$ , median PFS 6.3 months vs. 4.2 months). At the time of the second interim analysis for OS (data cut-off April 2024, with 52 % of pre-specified deaths for the final analysis reported), with a median follow-up of approximately 18.6 months for RYBREVANT-CP and approximately 17.8 months for CP, no statistically significant difference for OS between treatment arms was seen (HR=0.73; 95%CI: 0.54, 0.99; median OS 17.7 months vs. 15.3 months).

The ORR (data cut-off July 2023) was 63.8 % (95% CI: 55.0, 72.1) in the RYBREVANT-CP arm and 36.2% (95% CI: 30.3, 42.3) in the CP arm. In the RYBREVANT-CP arm 1.5% had a complete response and 62.3% a partial response vs. in the CP arm 0.4% had a complete response and 35.8% had a partial response.

### *Intracranial metastases efficacy data*

Patients with asymptomatic or previously treated and stable intracranial metastases were eligible for randomization to MARIPOSA-2. At inclusion in the study, 30 patients in the RYBREVANT+CP arm and 60 patients in the CP arm had intracranial metastases.

The intracranial objective response rate (ORR) was 23.3% (7 patients) in the RYBREVANT-CP arm and 16.7% (10 patients) in the CP arm (odds ratio of 1.52; 95% CI: 0.51,4.50).

### *Previously-treated NSCLC with EGFR exon-20 insertion mutations*

EDI1001 (CHRYSLIS) is a multicenter, open-label, multi-cohort study conducted to assess the safety and efficacy of RYBREVANT in subjects with locally advanced or metastatic NSCLC. Efficacy evaluated in 81 subjects with locally advanced or metastatic NSCLC who had EGFR Exon 20 insertion mutations, whose disease had progressed on or after platinum-based chemotherapy, and who had median follow-up of 9.7 months. Identification of an EGFR exon 20 insertion mutation was determined locally using next generation sequencing (NGS) or polymerase chain reaction (PCR) on tumor tissue or plasma samples. RYBREVANT was administered intravenously at 1050 mg for subjects <80 kg or 1400 mg for subjects ≥80 kg once weekly for 4 weeks, then every 2 weeks starting at week 5 thereafter until disease progression or unacceptable toxicity.

Patients with untreated brain metastases and patients with a history of ILD requiring treatment with prolonged steroids or other immunosuppressive agents within the last 2 years were not eligible for the study. Patients with planned invasive operative procedure, recent traumatic injury, expected major surgery 6 months after the last dose of study drug were also excluded. Intracranial responses were not assessed in the CHRYSLIS study.

The median age was 62 (range: 42–84) years, with 9% of the subjects ≥75 years of age; 59% were female; and 49% were Asian and 37% were White. The median number of prior therapies was 2 (range: 1 to 7 therapies). At baseline, 99% had ECOG performance status of 0 or 1 (99%); 53% never smoked; 75% had Stage IV cancer; and 22% had previous treatment for brain metastases. Insertions

in Exon 20 were observed at 8 different residues; the most common residues were A767 (24%), S768 (16%), D770 (11%), and N771 (11%).

Efficacy results are summarized in Table 10.

Table 10: Efficacy Results for EDI1001 (CHRYSALIS)

	Prior Platinum Chemotherapy Treated (N=81)
Overall Response Rate <sup>a,b</sup> (95% CI)	40% (29%, 51%)
Complete response	4%
Partial response	36%
Duration of Response <sup>a</sup> (DOR)	
Median (95% CI), months <sup>c</sup>	11.1 (6.9, NE)
Patients with DOR ≥ 6 months	63%
Median PFS <sup>a</sup> (95% CI), months	8.3 (6.5, 10.9)
Median OS (95% CI), months	22.8 (17.5, NE)

<sup>a</sup> Blinded Independent Central Review by RECIST v1.1

<sup>b</sup> Confirmed response.

<sup>c</sup> Based on Kaplan-Meier estimate.

NE=Not Estimable

### Pharmacokinetics

Based on RYBREVANT monotherapy data, amivantamab area under the concentration-time curve (AUC1 week) increases dose-proportionally over a dose range from 350 to 1750 mg.

#### Absorption

Based on the population pharmacokinetics of RYBREVANT, steady-state concentrations of RYBREVANT were reached by week 13 for both the 3-week and 2-week dosing regimen and the systemic accumulation was 1.9-fold.

#### Distribution

Amivantamab mean ± SD volume of distribution estimated from a population PK analysis was 5.34 ± 1.81 L following administration of the recommended dose of RYBREVANT.

#### Metabolism

No data.

### *Elimination*

The geometric mean (% CV) linear clearance (CL) and terminal half-life is 0.266 L/day (30.4%), and 13.7 days (31.9%), respectively.

### *Kinetics in specific patient groups*

#### *Hepatic impairment*

No clinically meaningful effect in the pharmacokinetics of amivantamab was observed based on mild hepatic impairment [(total bilirubin  $\leq$  ULN and AST  $>$  ULN) or (ULN  $<$  total bilirubin  $\leq$  1.5 x ULN)]. The effect of moderate (total bilirubin 1.5 to 3 times ULN) and severe (total bilirubin  $>$  3 times ULN) hepatic impairment on amivantamab pharmacokinetics was not examined.

#### *Renal impairment*

No clinically meaningful effect on the pharmacokinetics of amivantamab was observed in patients with mild ( $60 \leq$  creatinine clearance [CrCl]  $< 90$  mL/min) and moderate ( $29 \leq$  CrCl  $< 60$  mL/min) renal impairment. The effect of severe renal impairment ( $15 \leq$  CrCl  $< 29$  mL/min) on amivantamab pharmacokinetics was not examined.

#### *Elderly patients (65 years of age and older)*

No clinically meaningful differences in the pharmacokinetics of amivantamab were observed based on age (27-87 years).

#### *Children and adolescents (17 years of age and younger)*

The pharmacokinetics of RYBREVANT in pediatric patients have not been investigated.

#### *Gender*

The clearance of amivantamab was 24% higher in males than in females; however, this difference was assessed as not clinically meaningful.

#### *Weight*

The central volume of distribution and clearance of amivantamab increased with increasing body weight. Amivantamab exposures are 30-40% lower in patients who weighed  $\geq 80$  kg compared to patients with body weight  $< 80$  kg at the same dose. Similar amivantamab exposures were achieved at the recommended dose of RYBREVANT in patients with a body weight  $< 80$  kg who received 1050 mg and patients with a body weight  $\geq 80$  kg who received 1400 mg.

### **Preclinical data**

In repeat-dose toxicity studies in cynomolgus monkeys, amivantamab was well-tolerated at weekly doses up to 120 mg/kg intravenously for 6 weeks or 3 months ( $\sim 6$ - $8$ x  $C_{\max}$  and  $\sim 5$ - $7$ x AUC human exposure for 1050 and 1400 mg intravenous doses). There were no effects on cardiovascular,

respiratory, and nervous system function. Clinical pathology demonstrated non-adverse elevations in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and globulins, and non-adverse decreases in albumin when compared to the control group. All these values returned to normal ranges in recovery groups.

### *Carcinogenicity and Mutagenicity*

No animal studies have been performed to establish the carcinogenic and genotoxic potential of amivantamab.

### *Reproductive toxicity*

No reproductive toxicology studies have been performed to evaluate the potential effects of amivantamab.

## **Other information**

### *Incompatibilities*

This medicinal product may be mixed only with those medicinal products listed under “Instructions for handling”.

### *Shelf life*

Unopened vials:

Do not use this medicine after the expiry date marked as "EXP" on the pack.

### *Shelf life after opening*

After dilution:

The diluted preparation for infusion is not preserved.

Chemical and physical stability of the diluted solution has been demonstrated for 10 hours at 15-25 °C. For microbiological reasons, the diluted solution should be used immediately, unless the dilution has taken place in controlled and validated aseptic conditions. If the solution is not used immediately, storage times and conditions are the responsibility of the user.

Administer diluted solutions within 10 hours (including infusion time) at room temperature (15-25°C) and in room light.

### *Special precautions for storage*

Store in the refrigerator (2-8°C).

Do not freeze.

Store in the original packaging in order to protect the contents from light.

For storage conditions after dilution of the medicinal product, see “Shelf life after opening”.

Keep out of reach of children.

### *Instructions for handling*

#### *Preparation for Administration*

RYBREVANT solution must be diluted and prepared for intravenous infusion by a healthcare professional using aseptic technique (see also “Other Information”).

1. Determine the dose required and number of RYBREVANT vials needed based on patient’s baseline weight (see “Dosage/Administration” and table below). Each vial (7 ml) of RYBREVANT contains 350 mg of amivantamab.

Recommended Dose	Number of vials
1050 mg	3
1400 mg	4
1750 mg	5
2100 mg	6

2. Check that the RYBREVANT solution is colorless to pale yellow. Do not use if discoloration or visible particles are present.
3. Withdraw and then discard a volume of either 5% glucose solution or 0.9% sodium chloride solution from the 250 mL infusion bag equal to the volume of RYBREVANT to be added (i.e., discard 7 mL diluent from the infusion bag for each RYBREVANT vial). Infusion bags must be made of polyvinylchloride (PVC), polypropylene (PP), polyethylene (PE), or polyolefin blend (PP+PE).
4. Withdraw 7 mL of RYBREVANT from each vial and add it to the infusion bag. The final volume in the infusion bag should be 250 mL. Each vial contains a 0.5 mL overfill to ensure sufficient extractable volume. Discard any unused portion left in the vial.
5. Gently invert the bag to mix the solution. Do not shake.
6. Visually inspect the diluted solution before administration. Do not use if discoloration or visible particles are observed.
7. Diluted solutions should be administered within 10 hours (including infusion time) at room temperature (15°C to 25°C) and in room light.

#### *Administration*

1. Administer the diluted solution by intravenous infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.2 micrometer). Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), PVC, PP, or PE.
2. The infusion set with filter must be primed with the diluent (either 5% glucose solution or 0.9% sodium chloride solution) prior to each administration of RYBREVANT.
3. Do not infuse RYBREVANT concomitantly in the same intravenous line with other agents.

4. This medicinal product is for single use only. Any unused medicinal product should be disposed of in accordance with local requirements.

**Authorisation number**

68380 (Swissmedic).

**Packs**

Cartons with 1 single-use vial of 350mg/7mL [A].

**Marketing authorisation holder**

Janssen-Cilag AG, Zug, ZG

**Date of revision of the text**

October 2024